New Products Management 11e / Crawford & Di Benedetto Part V Launch
LEVITRA
Chapter 19
The drug industry is unique in that the products need to undergo years of extensive testing before
they are approved by the FDA for use, and that a blockbuster drug may easily account for over
half of the manufacturer’s sales and profits for a few years, until it goes off patent and becomes
much less profitable. Furthermore, even approval by the FDA is no guarantee of financial
success. So many additional factors can make or break a new drug product. Physicians actually
make the choice of drug in most cases, though they are not the product user, and physician
preferences will significantly impact the product’s future success. As some students may know,
Vioxx was approved by the FDA later than Celebrex, but initially overtook it, partially because
physicians liked the dosing regimen and felt patient compliance would be higher. Vioxx went on
to be one of the most financially successful drugs in the Merck product line, until the health risks
associated with its use caused it to be withdrawn suddenly from the market.
Levitra, the Glaxo-Bayer competitor to Pfizer’s Viagra, would seem to be a classic
illustration of finding a positioning gap left behind by a first mover (see chapter 6 discussion of
perceptual maps). While we don’t have customer data to build a formal perceptual map, the
Even if Levitra clearly surpasses Viagra on all of these dimensions, success is not
guaranteed, and that is where the launch strategy and management comes in. Here, Chapter 19
material can be effectively incorporated into the discussion. The launch of Levitra is detailed in
the case: the choice of spokesperson, tagline, sponsorship and advertising, distribution networks,
and price. All of these components will have to be managed, and sales tracked, to see what kind
of inroads Levitra is making against Viagra (and, in the future, any other competing drug by
another manufacturer). While there are no hard and fast answers, students may be asked to
critique these components of the launch strategy, prioritize them in terms of importance to
What happened? Both products coexist in the marketplace at the time of this writing and
both are successful. In mid 2004, Viagra entered a new phase of promotion. It was no longer the
only name, and primary demand promotion was no longer appropriate. A new promotional
campaign, featuring heavy television advertising, strongly reinforced Viagra as the brand that
would “get couples closer,” so to speak (this was the infamous campaign in which the blue V
14